Cardiovascular Disease

Changes in MetS Severity During Treatment Reflects Altered CVD Risk

Changes in MetS Severity During Treatment Reflects Altered CVD Risk

For patients with prediabetes who are randomly assigned to interventions, changes in risk indicators of metabolic syndrome (MetS) severity are associated with the risk for T2DM.

Differences in Sudden Cardiac Death Risk Noted Between Races

Differences in Sudden Cardiac Death Risk Noted Between Races

Sudden cardiac death rates are significantly higher among black adults than white adults without a history of cardiovascular disease.

Vitamin D Supplementation Does Not Lower Cardiovascular Event Incidence

Vitamin D Supplementation Does Not Lower Cardiovascular Event Incidence

By

Vitamin D supplementation did not lower the incidence of cancer or cardiovascular events compared with placebo.

Pregnancy Loss Associated With Greater Long-Term CVD Risk

Pregnancy Loss Associated With Greater Long-Term CVD Risk

Pregnancy loss was associated with a greater long-term risk for incident cardiovascular events.

Risks vs Benefits of Routine Prophylactic Aspirin in Patients Without Known Heart Disease

Risks vs Benefits of Routine Prophylactic Aspirin in Patients Without Known Heart Disease

By

The data presented in this study support the routine use of aspirin as recommended by the USPSTF.

Patterns of Cardiometabolic Health During Menopause Transition

Patterns of Cardiometabolic Health During Menopause Transition

By

Women entering menopause had patterns of cardiometabolic risk components related to race/ethnicity.

CMR May Detect Cardiac Complications in Lupus

CMR May Detect Cardiac Complications in Lupus

By

Researchers sought to determine whether a cardiovascular magnetic resonance protocol may be useful for early diagnosis of heart disease in patients with systemic lupus erythematosus.

Canagliflozin Approved to Reduce MACE Risk in Adults With Type 2 Diabetes and CVD

Canagliflozin Approved to Reduce MACE Risk in Adults With Type 2 Diabetes and CVD

By

The FDA has approved Invokana (canagliflozin) to reduce the risk of major CV events.

CT Abdominal Aortic Calcification Score Predicts CV Event Risk

CT Abdominal Aortic Calcification Score Predicts CV Event Risk

A computed tomography (CT)-based abdominal aortic calcification (AAC) score is a strong predictor of future cardiovascular events in asymptomatic patients.

Improved Cardiovascular Event Reporting Needed in Leukemia Clinical Trials

Improved Cardiovascular Event Reporting Needed in Leukemia Clinical Trials

By

Second- and third-generation tyrosine kinase inhibitors are associated with a variety of cardiovascular events.

High Variability in Metabolic Parameters May Predict All-Cause Mortality

High Variability in Metabolic Parameters May Predict All-Cause Mortality

By

High variability of fasting blood glucose and total cholesterol levels, systolic blood pressure, and BMI may be an independent predictor of cardiovascular events.

Cardiovascular Disease Risk Persists Years After Treatment of Thyrotoxicosis

Cardiovascular Disease Risk Persists Years After Treatment of Thyrotoxicosis

Excess cardiovascular disease mortality persisted for many years after thyroid-ablative treatment in patients who received radioactive iodine who did not become hypothyroid.

Significant Mortality Reduction With Empagliflozin in T2D and Established CVD

Significant Mortality Reduction With Empagliflozin in T2D and Established CVD

By

For this analysis, the authors used follow-up data from all 7020 patients included in the EMPA-REG OUTCOME trial to estimate the effect of empagliflozin on all-cause mortality vs placebo over the duration of a patient's lifetime.

Preventable CV Events: A Considerable Economic Burden in the United State

Preventable CV Events: A Considerable Economic Burden in the United State

Preventable cardiovascular events place a considerable health and economic burden on the United States.

Cardiovascular Risks Associated With Diclofenac Initiation

Cardiovascular Risks Associated With Diclofenac Initiation

By

Patients initiating diclofenac may have an increased risk for cardiovascular events compared with individuals using paracetamol, other traditional nonsteroidal anti-inflammatory drugs (NSAIDs), or those not taking NSAIDs.

Strategies to Reduce Cardiovascular Disease Risk Factors Yield Mixed Results

Strategies to Reduce Cardiovascular Disease Risk Factors Yield Mixed Results

CVD risk factors remain prevalent despite known, proven strategies to reduce risk.

Bipolar Disorder and the Cardiovascular System

Bipolar Disorder and the Cardiovascular System

By

Screening for cardiovascular disease risk is recommended for clinicians who manage patients with bipolar disorder.

Risk Factors for Atherosclerotic Cardiovascular Disease in the South Asian Population

Risk Factors for Atherosclerotic Cardiovascular Disease in the South Asian Population

By

South Asians exhibit the highest rates of ASCVD among all ethnic groups, and the highest prevalence is in younger age groups; up to 25% of myocardial infarctions in India occur in individuals younger than 40 years of age.

Fat Attenuation Index May Predict Adverse Cardiac Event Risk

Fat Attenuation Index May Predict Adverse Cardiac Event Risk

By

High perivascular fat attenuation index values are important markers of increased cardiac mortality and can guide targeted prevention strategies in this patient population.

Improved cardiovascular health associated with lower incidence of dementia in older adults

In this prospective cohort study, older patients with more optimal cardiovascular (CV) health metrics had a lower rate of developing dementia in a dose-dependent manner.

Central Obesity Not Predictive of Cardiovascular Events in Older Men

Central Obesity Not Predictive of Cardiovascular Events in Older Men

By

Central obesity might not be an effective predictor for atherosclerotic cardiovascular disease events in older men.

ASPREE Trial: Aspirin Associated With Higher Mortality, Hemorrhage Risk in Older Adults

ASPREE Trial: Aspirin Associated With Higher Mortality, Hemorrhage Risk in Older Adults

By

The use of aspirin in healthy elderly patients as a preventative strategy was associated with no prolongation of long-term disability-free survival compared with placebo.

Algorithm Can Discriminate CVD Risk Across Range of Health Profiles

Algorithm Can Discriminate CVD Risk Across Range of Health Profiles

The Cardiovascular Disease Population Risk Tool algorithm, which includes 12 variables, can discriminate cardiovascular disease risk.

Trends in Cardiovascular Deaths for US Adults With and Without Diabetes

Trends in Cardiovascular Deaths for US Adults With and Without Diabetes

By

Investigators used data from the National Health Interview Survey and follow-up mortality data to estimate trends and disparities in CVD.

New Clinical Chemistry Score More Sensitive, Specific Than hs-cTn in ACS

New Clinical Chemistry Score More Sensitive, Specific Than hs-cTn in ACS

A score based on the results of three laboratory tests has higher sensitivity and specificity than cardiac troponin alone for stratifying patients presenting with suspected acute coronary syndrome.

Hypertension and Heart Disease May Contribute to Brain Atrophy in MS

Hypertension and Heart Disease May Contribute to Brain Atrophy in MS

By

The presence of heart disease and hypertension may contribute to advanced brain atrophy in patients with multiple sclerosis.

Biologic Use Linked to Reduced Cardiovascular Risk in Inflammatory Arthritis

Biologic Use Linked to Reduced Cardiovascular Risk in Inflammatory Arthritis

By

Current biologic use was associated with a reduction in major cardiovascular events in patients with inflammatory arthritis.

Exposure to Toxic Metals May Increase Cardiovascular Disease Risk

Exposure to Toxic Metals May Increase Cardiovascular Disease Risk

Increased risk of cardiovascular disease and coronary heart disease with exposure to arsenic, lead, cadmium, and copper.

Tiotropium Associated With Increased Cardiovascular Risk in COPD

Tiotropium Associated With Increased Cardiovascular Risk in COPD

By

Cardiovascular risk within 30 days of therapy start was approximately 2-fold higher with the incident use of tiotropium in COPD.

Widespread Statin Use Not Recommended in Old, Very Old

Widespread Statin Use Not Recommended in Old, Very Old

No benefit in healthy elderly patients; the protective effect is limited to those with type 2 diabetes aged 75 to 84 years.

Sign Up for Free e-Newsletters